Articles publicats

Articles publicats 1 registres trobats  La cerca s'ha fet en 0.01 segons. 
1.
15 p, 3.0 MB Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis / Zozaya, Néboa (Universidad de Las Palmas de Gran Canaria) ; Abdalla, Fernando (Weber (Madrid)) ; Alfonso Zamora, Santiago (Psoriasis and Psoriatic Arthritis Patient and Family Association) ; Balea Filgueiras, Jesus (Complejo Hospitalario Universitario de Ferrol) ; Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Delgado Sánchez, Olga (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; Dolz Sinisterra, Francisco (Hospital Universitari Doctor Peset (València)) ; García-Ruiz, Antonio (Instituto de Investigación Biomédica de Málaga) ; Herranz Pinto, Pedro (Hospital Universitario La Paz (Madrid)) ; Manfredi, Antonio (Psoriasis and Psoriatic Arthritis Patient and Family Association) ; Martínez Olmos, José (Escuela Andaluza de Salud Pública (Granada, Andalusia)) ; Morales de Los Ríos Luna, Paloma (Hospital General Universitario Gregorio Marañón) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Ros Abarca, Sandra (Institut d'Investigació Biomèdica Sant Pau) ; Hidalgo-Vega, Álvaro (Universidad de Castilla-La Mancha) ; Universitat Autònoma de Barcelona
Background: Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and risankizumab. [...]
2022 - 10.1080/14737167.2022.2063842
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22 Núm. 6 (2022) , p. 941-953  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.